Queen Street Analytics

Sign in Subscribe

BioPharma

Queen Street Analytics' weekly digest of regulatory developments, legislative discussions, political announcements and other government-related news in biotech, pharmaceutical manufacturing, drug distribution and pricing, the life sciences and medical research.

QSA's Week in BioPharma (#10, 2025)

QSA's Week in BioPharma (#10, 2025)

Canada boosts biomanufacturing with $62M for Entos; Yukon, Nunavut, NWT sign rare disease drug agreements; Atlantic Canada bioscience incubator expands; Fentanyl precursor regulations updated; Canada invests in emerging tech networks.

QSA's Week in BioPharma (#9, 2025)

QSA's Week in BioPharma (#9, 2025)

Canada signs pharmacare agreements; Gairdner Awards funding boost; new PMPRB Chair appointed.

QSA's Week in BioPharma (#8, 2025)

QSA's Week in BioPharma (#8, 2025)

Pharmacare agreement signed; Private drug costs rise; Toxic drug crisis funding announced.

Lobbying Landscapes in BioPharma (Feb, 2025)

Lobbying Landscapes in BioPharma (Feb, 2025)

Terry Fox Research Institute; Pfizer Canada ULC; Genome Canada; Innovative Medicines Canada; Hoffmann-La Roche Limited; ZYUS Life Sciences Inc.

QSA's Week in BioPharma (#7, 2025)

QSA's Week in BioPharma (#7, 2025)

Canada invests in Eastern Ontario life sciences; Avian flu vaccine acquisition; HPV test expands in Quebec; BC addresses opioid crisis.

QSA's Week in BioPharma (#6, 2025)

QSA's Week in BioPharma (#6, 2025)

Investment in Southern Ontario life sciences; Repeal of food marketing authorizations; Call for fentanyl czar; Biotech market momentum.

QSA's Week in BioPharma (#5, 2025)

QSA's Week in BioPharma (#5, 2025)

Canadian Genomics Strategy launched; BC life sciences funding; Drug regulation amendments proposed; R&D personnel growth; Import/export permit changes.